↓ Skip to main content
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (74th percentile)
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

news
1 news outlet

Readers on

mendeley
9 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Article details
Title
Randomized double-blind phase II study of maintenance pembrolizumab versus placebo after first-line chemotherapy in patients (pts) with metastatic urothelial cancer (mUC): HCRN GU14-182.
Published in
Journal of Clinical Oncology, May 2019
DOI 10.1200/jco.2019.37.15_suppl.4504
Authors

Login to access the Attention Digest and the Sentiment Analysis related to this output.

Timeline Attention over time Attention Score history
Login to access the full charts related to this output.
Activity
Login to access the full charts related to this output.
Mendeley demographics

Mendeley demographics

The data shown below were compiled from readership statistics for 9 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Login to view Mendeley reader trends over time.

Geographical breakdown

Geographical breakdown
Country Count As %
Unknown 9 100%

Demographic breakdown

Readers by professional status
Readers by professional status Count As %
Researcher 1 11%
Student > Postgraduate 1 11%
Other 1 11%
Professor > Associate Professor 1 11%
Unknown 5 56%
Readers by discipline
Readers by discipline Count As %
Veterinary Science and Veterinary Medicine 1 11%
Pharmacology, Toxicology and Pharmaceutical Science 1 11%
Psychology 1 11%
Unknown 6 67%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 29 May 2020.
All research outputs
#4,267,193
of 23,211,181 outputs
Outputs from Journal of Clinical Oncology
#7,908
of 20,231 outputs
Outputs of similar age
#86,210
of 350,768 outputs
Outputs of similar age from Journal of Clinical Oncology
#180
of 559 outputs
Altmetric has tracked 23,211,181 research outputs across all sources so far. Compared to these this one has done well and is in the 80th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 20,231 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 19.8. This one has gotten more attention than average, scoring higher than 55% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 350,768 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 74% of its contemporaries.
We're also able to compare this research output to 559 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 50% of its contemporaries.